1. Home
  2. WPC vs INCY Comparison

WPC vs INCY Comparison

Compare WPC & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo W. P. Carey Inc. REIT

WPC

W. P. Carey Inc. REIT

HOLD

Current Price

$66.36

Market Cap

14.7B

Sector

Real Estate

ML Signal

HOLD

Logo Incyte Corp.

INCY

Incyte Corp.

HOLD

Current Price

$102.54

Market Cap

17.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WPC
INCY
Founded
1973
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Commercial Physical & Biological Resarch
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.7B
17.0B
IPO Year
1998
1993

Fundamental Metrics

Financial Performance
Metric
WPC
INCY
Price
$66.36
$102.54
Analyst Decision
Hold
Buy
Analyst Count
9
20
Target Price
$112.50
$90.71
AVG Volume (30 Days)
1.2M
2.0M
Earning Date
10-28-2025
10-28-2025
Dividend Yield
5.49%
N/A
EPS Growth
N/A
3878.02
EPS
1.65
5.90
Revenue
$1,670,291,000.00
$4,813,105,000.00
Revenue This Year
$7.52
$19.59
Revenue Next Year
$3.54
$10.88
P/E Ratio
$40.17
$17.37
Revenue Growth
5.29
18.09
52 Week Low
$52.91
$53.56
52 Week High
$69.79
$109.28

Technical Indicators

Market Signals
Indicator
WPC
INCY
Relative Strength Index (RSI) 43.85 54.83
Support Level $66.17 $100.55
Resistance Level $67.07 $107.61
Average True Range (ATR) 0.83 2.94
MACD -0.04 -0.98
Stochastic Oscillator 18.56 45.19

Price Performance

Historical Comparison
WPC
INCY

About WPC W. P. Carey Inc. REIT

W.P. Carey Inc is a real estate investment trust principally involved in the ownership of properties located in the U.S., Western Europe, and Northern Europe. W.P. Carey organizes its operations into Real Estate and Investment Management segments. The vast majority of the company's income is derived from its Real Estate division in the form of lease revenue from long-term agreements with companies. W.P. Carey's real estate portfolio is primarily comprised of single-tenant office, industrial, warehouse, and retail facilities located around the world. majority of the company's revenue comes from properties in the USA. Its Investment Management unit generates revenue from providing real estate advisory and portfolio management services to other REITs.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Share on Social Networks: